RECEIVED
CENTRAL FAX CENTER
NOV 0 9 2007

Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

1-20. (Canceled)

21. (Currently amended) A pharmaceutical composition comprising a Toll-like receptor 8 (TLR8) agonist that comprises a 2-aminopyridine fused to a five membered nitrogen-containing heterocyclic ring, or a pharmaceutically acceptable salt thereof, in an amount effective to modulate at least one TLR8-mediated cellular signaling pathway in combination with a pharmaceutically acceptable carrier~~, wherein the TLR8 agonist comprises a substituted imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, a thiazolonaphthyridine amine, a 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amine, a 1*H*-imidazo dimer fused to a pyridine amine, quinoline amine, tetrahydroquinoline amine, naphthyridine amine, or tetrahydronaphthyridine amine, a purine derivative, an imidazoquinoline amide derivative, an imidazopyridine derivatives, a benzimidazole derivative, a derivative of a 4-aminopyrimidine fused to a five-membered nitrogen-containing heterocyclic ring, or a 3-β-D-ribofuranosylthiazolo[4,5-*d*]pyrimidine derivative~~.

22-29. (Canceled)

30. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a substituted imidazoquinoline amine.

31. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a tetrahydroimidazoquinoline amine.

32. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an imidazopyridine amine.

33. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a 1,2-bridged imidazoquinoline amine.

34. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a 6,7-fused cycloalkylimidazopyridine amine.

35. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an imidazonaphthyridine amine.

36. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a tetrahydroimidazonaphthyridine amine.

37. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an oxazoloquinoline amine.

38. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a thiazoloquinoline amine.

39. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an oxazolopyridine amine.

40. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a thiazolopyridine amine.

41. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an oxazolonaphthyridine amine.

42. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a thiazolonaphthyridine amine.

43. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amine.

44. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a 1*H*-imidazo dimer fused to a pyridine amine, quinoline amine, tetrahydroquinoline amine, naphthyridine amine, or tetrahydronaphthyridine amine.

45. (New) The pharmaceutical composition of claim 38, wherein the thiazoloquinoline amine is 2-propylthiazolo[4,5-c]quinolin-4-amine.